Podcasts

He discusses his research that evaluated whether β-2 glycoprotein 1 IgA antibodies can predict coronary plaque burden and progression, and whether the antibodies moderate the effect of inflammation on atherosclerosis among patients with rheumatoid arthritis.

He talks about his study that evaluated whether biologic disease-modifying antirheumatic drugs reduce long-term risk of cardiovascular events in patients with rheumatoid arthritis, as well as their mechanism of action.

He talks about his study that evaluated the impact of inflammation, cardiac risk factors, duration of medication exposure, and their interactions on coronary plaque progression among patients with rheumatoid arthritis.

In the second installment, Dr Green and Dr Gelfand discuss the impact of the COVID-19 pandemic and how they are managing patients with psoriasis.

Joel Gelfand, MD, is one of the pioneering researchers who showed a connection between psoriasis and the risk of cardiovascular disease (CVD). In this podcast, Lawrence Green, MD, interviews Dr Gelfand on the latest research in CVD and psoriasis.

He talks about how vaccinations affect individuals with immunocompromised immune systems, the challenges associated with vaccination, and what rheumatologists should know about vaccines in 2020.

There are many questions regarding the best way to manage patients with psoriasis during the coronavirus pandemic, particularly patients on systemic therapies. Dr Lawrence Green discusses how to address patients’ concerns, maintaining a safe work environment if you choose to keep your practice open…

In this podcast, Adam Friedman, MD, professor of dermatology and interim chair of the department of dermatology at George Washington Medical School, discusses off label uses of various therapies in dermatology, tips for counseling patients, and pearls for getting coverage from insurance companies.

Dr Pimentel, from Cedars-Sinai, discusses the current challenges of IBS management, how food poisoning and a low fermentation diet impact the disease, promising strategies for the future, and more.

Anti-tumor necrosis factor agents and/or thiopurines can prevent recurrence of Crohn disease in surgically treated patients, said Miguel Regueiro, MD, from the Cleveland Clinic, at the 2019 AIBD Meeting.